Herbal medicines in the treatment of psychiatric disorders: A systematic review

Phytotherapy Research

Volumn 21, Issue 8, 2007, Pages 703-716

  Sarris, Jerome ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Complementary medicine; Herbal medicine; Medicinal plants; Mood disorders; Psychiatric disorders; Psychiatry

Indexed keywords

4 AMINOBUTYRIC ACID; AMITRIPTYLINE; AYURVEDIC DRUG; CITALOPRAM; CROCUS SATIVUS EXTRACT; DOPAMINE; EPHEDRA SINICA EXTRACT; FLUOXETINE; GLYCOPROTEIN P; GS 02; HERBACEOUS AGENT; HYPERFORIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; IMIPRAMINE; JUJUBE EXTRACT; KAVA EXTRACT; LAVENDER OIL; MAPROTILINE; NORADRENALIN; OXAZEPAM; PAROXETINE; PASSIFLORA INCARNATA EXTRACT; PLACEBO; PM 235; PREGNANE X RECEPTOR; RHODIOLA ROSEA EXTRACT; SCUTELLARIA LATERIFLORA EXTRACT; SEROTONIN; SERTRALINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WS 5570; WS 5572; WS 5573;

ANXIETY DISORDER; BIPOLAR DISORDER; CLINICAL TRIAL; COCHRANE LIBRARY; DEPRESSION; DRUG SAFETY; DYSTHYMIA; GASTROINTESTINAL SYMPTOM; GENERALIZED ANXIETY DISORDER; HERBAL MEDICINE; HUMAN; JUJUBE; LIVER FAILURE; LIVER TOXICITY; MANIA; MEDICINAL PLANT; MEDLINE; MOOD DISORDER; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; PANIC; PHOBIA; PHYTOTHERAPY; PSYCHOSIS; RESEARCH PRIORITY; REVIEW; SCHIZOPHRENIA; SCUTELLARIA; SCUTELLARIA LATERIFLORA; SEASONAL AFFECTIVE DISORDER; SEROTONIN SYNDROME; SKIN DISEASE; SOCIAL PHOBIA; SOMATOFORM DISORDER; SYSTEMATIC REVIEW;

HUMANS; MEDICINE, HERBAL; PHYTOTHERAPY; PLANT EXTRACTS; PSYCHOTIC DISORDERS;

CROCUS SATIVUS; PASSIFLORA; PASSIFLORA INCARNATA; PIPER METHYSTICUM; RHODIOLA ROSEA; SCUTELLARIA LATERIFLORA; ZIZIPHUS JUJUBA;

EID: 34547666959     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.2187     Document Type: Review

References (168)

1. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH, Khalighi-Cigaroudi F. 2004. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: a pilot double-blind randomized trial. BMC Complement Altern Med 4: 12.
2. Akhondzadeh S, Kashani L, Fotouhi A et al. 2003. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 27: 123-127.
3. Akhondzadeh S, Naghavi HR, Vazirian M, Shayeganpour A, Rashidi H, Khani M. 2001. Passionflower in the treatment of generalized anxiety: a pilot double-blind randomized controlled trial with oxazepam. J Clin Pharm Ther 26: 363-367.
4. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA et al. 2005. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial. Phytother Res 19: 148-151.
5. Altman DG, Schulz KF, Moher D et al. 2001. The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134: 663-694.
6. American Psychiatric Association. 2000. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association: Washington, DC.
7. Andrade C, Aswath A, Chaturvedi SK, Raguram R, Srinivasa M. 2002. GS-02 for dysthymic disorder: results of a preliminary, open study. J Herb Pharmacother 2: 49-55.
8. Andreatini R, Sartori VA, Seabra ML, Leite JR. 2002. Effect of valepotriates (valerian extract) in generalized anxiety disorder: a randomized placebo-controlled pilot study. Phytother Res 16: 650-654.
9. Anke J, Ramzan I. 2004. Kava hepatotoxicity: Are we any closer to the truth? Planta Med 70: 193-196.
10. Antai-Otong D. 2003. Current treatment of generalized anxiety disorder. J Psychosoc Nurs Ment Health Serv 41: 20-29.
11. Awad R, Arnason JT, Trudeau V et al. 2003. Phytochemical and biological analysis of skullcap (Scutellaria lateriflora L.): a medicinal plant with anxiolytic properties. Phytomedicine 10: 640-649.
12. Baghai TC, Volz HP, Moller HJ. 2006. Drug treatment of depres-sion in the 2000s: An overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 7: 198-222.
13. Bauer R. 2003. Relevant hepatotoxicity effects of Kava still need to be proven. Planta Med 69: 971-972.
14. Beaubrun G, Gray GE. 2000. A review of herbal medicines for psychiatric disorders. Psychiatr Serv 51: 1130-1134.
15. Behnke K, Jensen GS, Graubaum HJ, Gruenwald J. 2002. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression. Adv Ther 19: 43-52.
16. Beijamini V, Andreatini R. 2003. Effects of Hypericum perforatum and paroxetine on rat performance in the elevated T-maze. Pharmacol Res 48: 199-207.
17. Bensky D, Gamble A. 1991. Chinese Herbal Formulas. Eastland Press: Seattle.
18. Bensky D, Gamble A. 1993. Chinese Herbal Medicine Material Medica. Eastland Press: Seattle.
19. Berton O, Nestler EJ. 2006. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 7: 137-151.
20. Bhattacharya SK, Bhattacharya A, Sairam K, Ghosal S. 2000. Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: an experimental study. Phytomedicine 7: 463-469.
21. Bhattacharya SK, Muruganandam AV. 2003. Adaptogenic activity of Withania somnifera: an experimental study using a rat model of chronic stress. Pharmacol Biochem Behav 75: 547-555.
22. Bjerkenstedt L, Edma, GV, Alken RG, Mannel M. 2005. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients. Eur Arch Psychiatry Clin Neurosci 255: 40-47.
23. Blumenthal M. 2000. The Complete Expanded German Commission E Monographs: Therapeutic Guide To Herbal Medicines. American Botanical Council: Austin.
24. Boerner RJ. 2001. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia. Phytother Res 15: 646-647.
25. Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M. 2003. Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder - an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients. Phytomedicine 10 (Suppl 4): 38-49.
26. Boerth JM, Caley CF. 2003. Possible case of mania associated with ma-huang. Pharmacotherapy 23: 380-383.
27. Bone K. 2003. A Clinical Guide to Blending Liquid Herbs: Herbal Formulations for the Individual Patient. Churchill & Livingstone: China.
28. Borgert CJ, Borgert SA, Findley KC. 2005. Synergism, antagonism, or additivity of dietary supplements: application of theory to case studies. Thromb Res 117: 123-132.
29. Bradfield JW. 2006. A pathologist's perspective of the somatoform disorders. J Psychosom Res 60: 327-330.
30. Bradwejn J, Zhou Y, Koszycki D, Shlik J. 2000. A double-blind, placebo-controlled study on the effects of Gotu Kola (Centella asiatica) on acoustic startle response in healthy subjects. J Clin Psychopharmacol 20: 680-684.
31. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M. 2000. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study. Clin Ther 22: 411-419.
32. Butterweck V. 2003. Mechanism of action of St John's wort in depression: what is known? CNS Drugs 17: 539-562.
33. Cagnacci A, Arangino S, Renzi A, Zanni AL, Malmusi S, Volpe A. 2003. Kava-Kava administration reduces anxiety in perimenopausal women. Maturitas 44: 103-109.
34. Chen HC, Hsieh MT, Lai E. 1985. Studies on the suanzaorentang in the treatment of anxiety. Psychopharmacology (Berl) 85: 486-487.
35. Clement K, Covertson CR, Johnson MJ, Dearing K. 2006. St John's wort and the treatment of mild to moderate depression: a systematic review. Holist Nurs Pract 20: 197-203.
36. Clouatre DL. 2004. Kava kava: examining new reports of toxicity. Toxicol Lett 150: 85-96.
37. Clough AR, Bailie RS, Currie B. 2003. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol 41: 821-829.
38. Culpeper N. 1652. Culpeper's Complete Herbal. Wordsworth Editions Ltd: Hertfordshire.
39. Currier GW, Trenton A. 2002. Pharmacological treatment of psychotic agitation. CNS Drugs 16: 219-228.
40. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. 1992. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 71: 120-126.
41. Degner D, Grohmann R, Kropp S et al. 2004. Severe adverse drug reactions of antidepressants: results of the German multicentre drug surveillance program AMSP. Pharmacopsychiatry 37 (Suppl 1): 39-45.
42. Dhawan K, Kumar S, Sharma A. 2002. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata Linneaus: a comment on medicinal plants standardization. J Altern Complement Med 8: 283-291.
43. Dresser GK, Schwarz Ul, Wilkinson GR, Kim RB. 2003. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. Clin Pharmacol Ther 73: 41-50.
44. Ernst E. 2006. Herbal remedies for anxiety - a systematic review of controlled clinical trials. Phytomedicine 13: 205-208.
45. Fahmi M, Huang C, Schweitzer I. 2002. A case of mania induced by hypericum. World J Biol Psychiatry 3: 58-59.
46. Fava M, Alpert J, Nierenberg AA et al. 2005. A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25: 441-447.
47. Felter HW, Lloyd JU. 2006 (1898). King's American Dispensatory. http://www.ibiblio.org/herbmed/eclectic/kings/main.html
48. Findling RL, McNamara NK, O'Riordan MA et al. 2003. An open-label pilot study of St John's wort in juvenile depression. J Am Acad Child Adolesc Psychiatry 42: 908-914.
49. Franklin M, Hafizi S, Reed A, Hockney R, Murck H. 2006. Effect of sub-chronic treatment with Jarsin (extract of St John's wort, Hypericum perforatum) at two dose levels on evening salivary melatonin and cortisol concentrations in healthy male volunteers. Pharmacopsychiatry 39: 13-15.
50. Gagnier JJ, Boon H, Rochon P, Moher D, Barnes J, Bombardier C. 2006. Reporting randomized, controlled trials of herbal interventions: an elaborated CONSORT statement. Ann Intern Med 144: 364-367.
51. Gastpar M, Singer A, Zeller K. 2005. Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once-daily dosage in comparison with sertraline. Pharmacopsychiatry 38: 78-86.
52. Gastpar M, Singer A, Zeller K. 2006. Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study. Pharmacopsychiatry 39: 66-75.
53. Gurley BJ, Gardner SF, Hubbard MA et al. 2005. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther 77: 415-426.
54. Guzelcan Y, Scholte WF, Assies J, Becker HE. 2001. [Mania during the use of a combination preparation with St. John's wort (Hypericum perforatum)]. Ned Tijdschr Geneeskd 145: 1943-1945.
55. Hadley S, Petry JJ. 2003. Valerian. Am Fam Physician 67: 1755-1758.
56. Hanus M, Lafon J, Mathieu M. 2004. Double-blind, randomised, placebo-controlled study to evaluate the efficacy and safety of a fixed combination containing two plant extracts (Crataegus oxyacantha and Eschscholtzia californica) and magnesium in mild-to-moderate anxiety disorders. Curr Med Res Opin 20: 63-71.
57. Harrer G, Hubner WD, Podzuweit H. 1994. Effectiveness and tolerance of the hypericum extract LI 160 compared to maprotiline: a multicenter double-blind study. J Geriatr Psychiatry Neurol 7 (Suppl 1): 24-28.
58. Hsieh MT, Chen HC, Hsu PH, Shibuya T. 1986a. Effects of Suanzaorentang on behavior changes and central monoamines. Proc Natl Sci Counc Repub China B 10: 43-48.
59. Hsieh MT, Chen HC, Kao HC, Shibuya T. 1986b. Suanzaorentang, and anxiolytic Chinese medicine, affects the central adrenergic and serotonergic systems in rats. Proc Natl Sci Counc Repub China B 10: 263-268.
60. Hunt C, Issakidis C, Andrews G. 2002. DSM-IV generalized anxiety disorder in the Australian National Survey of Mental Health and Weil-Being. Psychol Med 32: 649-659.
61. Hunt C, Slade T, Andrews G. 2004. Generalized Anxiety Disorder and major depressive disorder comorbidity in the National Survey of Mental Health and Well-Being. Depress Anxiety 20: 23-31.
62. Hypericum Depression Trial Study Group. 2002. Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial. JAMA 287: 1807-1814.
63. Izzo AA. 2004. Drug interactions with St John's wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther 42: 139-148.
64. Jacobs BP, Bent S, Tice JA, Blackwell T, Cummings SR. 2005. An internet-based randomized, placebo-controlled trial of kava and valerian for anxiety and insomnia. Medicine (Baltimore) 84: 197-207.
65. Jussofie A, Schmiz A, Hiemke C. 1994. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 116: 469-474.
66. Kelly GS. 2001. Rhodiola rosea: a possible plant adaptogen. Altern Med Rev 6: 293-302.
67. Kennedy DO, Little W, Haskell CF, Scholey AB. 2006. Anxiolytic effects of a combination of Melissa officinalis and Valeriana officinalis during laboratory induced stress. Phytother Res 20: 96-102.
68. Kennedy DO, Little W, Scholey AB. 2004. Attenuation of laboratory-induced stress in humans after acute administration of Melissa officinalis (Lemon Balm). Psychosom Med 66: 607-613.
69. Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. 2002. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav 72: 953-964.
70. Kessler RC, Berglund P, Demler O et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 289: 3095-3105.
71. Knuppel L, Linde K. 2004. Adverse effects of St John's Wort: a systematic review. J Clin Psychiatry 65: 1470-1479.
72. Kobak KA, Taylor LV, Bystritsky A et al. 2005a. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 20: 299-304.
73. Kobak KA, Taylor LV, Warner G, Futterer R. 2005b. St. John's wort versus placebo in social phobia: results from a placebo-controlled pilot study. J Clin Psychopharmacol 25: 51-58.
74. Kroenke K, Rosmalen JG. 2006. Symptoms, syndromes, and the value of psychiatric diagnostics in patients who have functional somatic disorders. Med Clin North Am 90: 603-626.
75. Kucinskaite A, Briedis V, Savickas A. 2004. [Experimental analysis of therapeutic properties of Rhodiola rosea L. and its possible application in medicine]. Medicina (Kaunas) 40: 614-619.
76. Kuribara H, Iwata H, Tomioka H et al. 2001. The anxiolytic effect of Sho-ju-sen, a Japanese herbal medicine, assessed by an elevated plus-maze test in mice. Phytother Res 15: 142-147.
77. Laakmann G, Schule C, Baghai T, Kieser M. 1998. St John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry 31 (Suppl 1): 54-59.
78. Larzelere MM, Wiseman P. 2002. Anxiety, depression, and insomnia. Prim Care 29: 339-360.
79. Lawvere S, Mahoney MC. 2005. St John's wort. Am Fam Physician 72: 2249-2254.
80. Lecrubier Y. 2006. Physical components of depression and psychomotor retardation. J Clin Psychiatry 67 (Suppl 6): 23-26.
81. Leite JR, Seabra M, Maluf E et al. 1986. Pharmacology of lemongrass (Cymbopogon citratus Stapf). III. Assessment of eventual toxic, hypnotic and anxiolytic effects on humans. J Ethnopharmacol 17: 75-83.
82. Li JM, Yang C, Zhang WY, Kong LD. 2003. [The effects of banxia houpu decoction on a chronic mild stress model of depression]. Zhongguo Zhong Yao Za Zhi 28: 55-59.
83. Li Y, Wang R, Chen M, Wang Z, Bi K. 2001. [Pharmacodynamics study of suanzaoren decoction extracted by different technological process]. Zhong Yao Cai 24: 884-885.
84. Lin YC, Hsieh MT, Chen CF, Cheng HY, Peng WH. 2003. Anxiolytic effect of ting-chih-wan in mouse behavior models of anxiety. Am J Chin Med 31: 47-59.
85. Linde K, Mulrow CD, Berner M, Egger M. 2005. St John's wort for depression. Cochrane Database Syst Rev 2, CD000448.
86. Lingaerde O, Foreland AR, Magnusson A. 1999. Can winter depression be prevented by Ginkgo biloba extract? A placebo-controlled trial. Acta Psychiatr Scand 100: 62-66.
87. Luo HC, Qian RQ, Zhao XY et al. 2006. [Clinical observation on effect of danzhi xiaoyao powder in treating depression]. Zhongguo Zhong Xi Yi Jie He Za Zhi 26: 212-214.
88. Luo L, Nong Wang J, Kong LD, Jiang QG, Tan RX. 2000. Anti-depressant effects of Banxia Houpu decoction, a traditional Chinese medicinal empirical formula. J Ethnopharmacol 73: 277-281.
89. Ma Y, Sachdeva K, Liu J et al. 2004. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos 32: 1317-1324.
90. Maglione M, Miotto K, Iguchi M, Hilton L, Shekelle P. 2005. Psychiatric symptoms associated with ephedra use. Expert Opin Drug Saf 4: 879-884.
91. Magnusson A, Partonen T. 2005. The diagnosis, symptomatology, and epidemiology of seasonal affective disorder. CNS Spectr 10: 625-634.
92. Mantani N, Hisanaga A, Kogure T, Kita T, Shimada Y, Terasawa K. 2002. Four cases of panic disorder successfully treated with Kampo (Japanese herbal) medicines: Kami-shoyo-san and Hange-koboku-to. Psychiatry Clin Neurosci 56: 617-620.
93. Martinez B, Kasper S, Ruhrmann S, Moller HJ. 1994. Hypericum in the treatment of seasonal affective disorders. J Geriatr Psychiatry Neurol 7 (Suppl 1): 29-33.
94. Mathews JM, Etheridge AS, Black SR. 2002. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab Dispos 30: 1153-1157.
95. Mennini T, Gobbi M. 2004. The antidepressant mechanism of Hypericum perforatum. Life Sci 75: 1021-1027.
96. Miller LG. 1998. Herbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med 158: 2200-2211.
97. Mills S, Bone K. 2000. Principles and Practice of Phytotherapy. Churchill Livingstone: London.
98. Miyasaka LS, Atallah AN, Soares BG. 2006. Valerian for anxiety disorders. Cochrane Database Syst Rev 4: CD004515.
99. Mohr P, Pecenak J, Svestka J, Swingler D, Treuer T. 2005. Treatment of acute agitation in psychotic disorders. Neuro Endocrinol Lett 26: 327-335.
100. Moore LB, Goodwin B, Jones SA et al. 2000. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97: 7500-7502.
101. Moreno RA, Teng CT, Almeida KM, Tavares Jr H. 2006. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample. Rev Bras Psiquiatr 28: 29-32.
102. Morishita S, Mishima Y, Hirai Y, Saito T, Shoji M. 1987. Pharmacological studies of water extract of the Zizyphus seed and the Zizyphus seed containing drug. Gen Pharmacol 18: 637-641.
103. Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin Abbasi S, Akhondzadeh S. 2006. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine 13: 607-611.
104. Mueller SC, Majcher-Peszynska J, Uehleke B et al. 2006. The extent of induction of CYP3A by St John's wort varies among products and is linked to hyperforin dose. Eur J Clin Pharmacol 62: 29-36.
105. Muller D, Pfeil T, von den Driesch V. 2003. Treating depression comorbid with anxiety - results of an open, practice-oriented study with St John's wort WS 5572 and valerian extract in high doses. Phytomedicine 10 (Suppl 4): 25-30.
106. Muller SF, Klement S. 2006. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. Phytomedicine 13: 383-387.
107. Muller T, Mannel M, Murck H, Rahlfs VW. 2004. Treatment of somatoform disorders with St John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med 66: 538-547.
108. Murck H, Fava M, Alpert J et al. 2005. Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol 8: 215-221.
109. Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349: 1498-1504.
110. Nemeroff CB. 2003. Improving antidepressant adherence. J Clin Psychiatry 64 (Suppl 18): 25-30.
111. Nierenberg AA, Burt T, Matthews J, Weiss AP. 1999. Mania associated with St. John's wort. Biol Psychiatry 46: 1707-1708.
112. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. 2005. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: a double-blind, randomized pilot trial. J Ethnopharmacol 97: 281-284.
113. Pirotta MV, Cohen MM, Kotsirilos V, Farish SJ. 2000. Complementary therapies: have they become accepted in general practice? Med J Aust 172: 105-109.
114. Pittler MH, Ernst E. 2006. Kava extract for treating anxiety. Cochrane Database Syst Rev 1, CD003383.
115. Pittler MH, Schmidt K, Ernst E. 2003. Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials. Am J Med 114: 665-674.
116. Randlov C, Mehlsen J, Thomsen CF, Hedman C, von Fircks H, Winther K. 2006. The efficacy of St John's wort in patients with minor depressive symptoms or dysthymia - a double-blind placebo-controlled study. Phytomedicine 13: 215-221.
117. Rathbone J, Zhang L, Zhang M, Xia J, Liu X, Yang Y. 2005. Chinese herbal medicine for schizophrenia. Cochrane Database Syst Rev 4: CD003444.
118. Rex A, Morgenstern E, Fink H. 2002. Anxiolytic-like effects of kava-kava in the elevated plus maze test - a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 26: 855-860.
119. Rickels K, Rynn M. 2002. Pharmacotherapy of generalized anxiety disorder. J Clin Psychiatry 63 (Suppl 14): 9-16.
120. Rigelsky JM, Sweet BV. 2002. Hawthorn: pharmacology and therapeutic uses. Am J Health Syst Pharm 59: 417-422.
121. Roder C, Schaefer M, Leucht S. 2004. [Meta-analysis of effectiveness and tolerability of treatment of mild to moderate depression with St John's wort]. Fortschr Neurol Psychiatr 7: 330-343.
122. Rodriguez-Landa JF, Contreras CM. 2003. A review of clinical and experimental observations about antidepressant actions and side effects produced by Hypericum perforatum extracts. Phytomedicine 10: 688-699.
123. Rolland A, Fleurentin J, Lanhers MC, Misslin R, Mortier F. 2001. Neurophysiological effects of an extract of Eschscholzia californica Cham. (Papaveraceae). Phytother Res 15: 377-381.
124. Rolland A, Fleurentin J, Lanhers MC et al. 1991. Behavioural effects of the American traditional plant Eschscholzia californica: sedative and anxiolytic properties. Planta Med 57: 212-216.
125. Sartorius N, Ustun TB, Lecrubier Y, Wittchen HU. 1996. Depression comorbid with anxiety: results from the WHO study on psychological disorders in primary health care. Br J Psychiatry (Suppl)30: 38-43.
126. Sayyah M, Sayyah M, Kamalinejad M. 2006. A preliminary randomized double blind clinical trial on the efficacy of aqueous extract of Echium amoenum in the treatment of mild to moderate major depression. Prog Neuropsychopharmacol Biol Psychiatry 30: 166-169.
127. Schrader E. 2000. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15: 61-68.
128. Schule C, Baghai T, Ferrera A, Laakmann G. 2001. Neuroendocrine effects of Hypericum extract WS 5570 in 12 healthy male volunteers. Pharmacopsychiatry 34 (Suppl 1): 127-133.
129. Schulz V. 2006. Safety of St John's wort extract compared to synthetic antidepressants. Phytomedicine 13: 199-204.
130. Shelton RC, Keller MB, Gelenberg A et al. 2001. Effectiveness of St John's wort in major depression: a randomized controlled trial. JAMA 285: 1978-1986.
131. Shevtsov VA, Zholus Bl, Shervarly VI et al. 2003. Randomized trial of two different doses of a SHR-5 Rhodiola rosea extract versus placebo and control of capacity for mental work. Phytomedicine 10: 95-105.
132. Simeon J, Nixon MK, Milin R, Jovanovic R, Walker S. 2005. Open-label pilot study of St John's wort in adolescent depression. J Child Adolesc Psychopharmacol 15: 293-301.
133. Singh B. 2005. Recognition and optimal management of schizophrenia and related psychoses. Intern Med J 35: 413-418.
134. Singh YN. 2005. Potential for kava and St John's wort with drugs. J Ethnopharmacol 100: 108-113.
135. Singh YN, Singh NN. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16: 731-743.
136. Sorrentino L, Capasso A, Schmidt M. 2006. Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats. Phytomedicine 13: 542-549.
137. Spinella M, Eaton LA. 2002. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 16: 359-367.
138. Stevinson C, Ernst E. 2004. Can St. John's wort trigger psychoses? Int J Clin Pharmacol Ther 42: 473-480.
139. Stevinson C, Huntley A, Ernst E. 2002. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 25: 251-261.
140. Stough C, Lloyd J, Clarke J et al. 2001. The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl) 156: 481-484.
141. Szegedi A, Kohnen R, Dienel A, Kieser M. 2005. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine. Br Med J 330: 503.
142. Taylor LH, Kobak KA. 2000. An open-label trial of St John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 61: 575-578.
143. Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. 2002. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med 68: 1055-1058.
144. van Gurp G, Meterissian GB, Haiek LN, McCusker J, Bellavance F. 2002. St John's wort or sertraline? Randomized controlled trial in primary care. Can Fam Physician 48: 905-912.
145. Vandenbogaerde A, Zanoli P, Puia G et al. 2000. Evidence that total extract of Hypericum perforatum affects exploratory behavior and exerts anxiolytic effects in rats. Pharmacol Biochem Behav 65: 627-633.
146. Vazquez I, Aguera-Ortiz LF. 2002. Herbal products and serious side effects: a case of ginseng-induced manic episode. Acta Psychiatr Scand 105: 76-77.
147. Volz HP, Murck H, Kasper S, Moller HJ. 2002. St John's wort extract (LI 160) in somatoform disorders: results of a placebo-controlled trial. Psychopharmacology (Berl) 164: 294-300.
148. Walker AF, Marakis G, Morris AP, Robinson PA. 2002. Promising hypotensive effect of hawthorn extract: a randomized double-blind pilot study of mild, essential hypertension. Phytother Res 16: 48-54.
149. Wang Y, Kong L, Chen Y. 2005. Behavioural and biochemical effects of fractions prepared from Banxia Houpu decoction in depression models in mice. Phytother Res 19: 526-529.
150. Watkins LL, Connor KM, Davidson JR. 2001. Effect of kava extract on vagal cardiac control in generalized anxiety disorder: preliminary findings. J Psychopharmacol 15: 283-286.
151. Wheatley D. 1997. LI 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry 30 (Suppl 2): 77-80.
152. Wheatley D. 1999. Hypericum in seasonal affective disorder (SAD). Curr Med Res Opin 15: 33-37.
153. Wheatley D. 2001. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol 16: 353-356.
154. WHO. 2006. Mental Health 'Depression. http://www.who.int/mental_health/ management/depression/definition/en/
155. Williamson EM. 2001. Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-409.
156. Williamson G, Day AJ, Plumb GW, Couteau D. 2000. Human metabolic pathways of dietary flavonoids and cinnamates. Biochem Soc Trans 28: 16-22.
157. Witte S, Loew D, Gaus W. 2005. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 19: 183-188.
158. Woelk H. 2000. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial. Br Med J 321: 536-539.
159. Woelk H, Arnoldt KH, Kieser M, Hoerr R. 2007. Ginkgo biloba special extract EGb 761((R)) in generalized anxiety disorder and adjustment disorder with anxious mood: A randomized, double-blind, placebo-controlled trial. J Psychiatr Res 41: 472-480.
160. Wolfson P, Hoffmann DL. 2003. An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers. Altern Ther Health Med 9: 74-78.
161. Wong AHC, Smith M, Boon HS. 1998. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 55: 1033-1044.
162. Wurglics M, Schubert-Zsilavecz M. 2006. Hypericum perforatum: a 'modern' herbal antidepressant: pharmacokinetics of active ingredients. Clin Pharmacokinet 45: 449-468.
163. Yuan CS, Dey L, Wang A et al. 2002. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastricbrainstem preparation. Planta Med 68: 1092-1096.
164. Yuzurihara M, Ikarashi Y, Ishige A Sasaki H, Maruyama Y. 2000. Anxiolytic-like effect of saiboku-to, an oriental herbal medicine, on histaminergics-induced anxiety in mice. Pharmacol Biochem Behav 67: 489-495.
165. Zanoli P. 2004. Role of hyperforin in the pharmacological activities of St John's wort. CNS Drug Rev 10: 203-218.
166. Zhang M, Ning G, Shou C, Lu Y, Hong D, Zheng X. 2003. Inhibitory effect of jujuboside A on glutamate-mediated excitatory signal pathway in hippocampus. Planta Med 69: 692-695.
167. Zhang ZJ, Kang WH, Tan QR et al. 2001. Adjunctive herbal medicine with carbamazepine for bipolar disorders: A double-blind, randomized, placebo-controlled study. J Psychiatr Res 41: 360-369.
168. Zhou D, Zhang X, Su J et al. 1999. The effects of classic antipsychotic haloperidol plus the extract of Ginkgo biloba on superoxide dismutase in patients with chronic refractory schizophrenia. Chin Med J (Engl) 112: 1093-1096.